Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P62330
UPID:
ARF6_HUMAN
Alternative names:
-
Alternative UPACC:
P62330; P26438; Q6FGZ2
Background:
ADP-ribosylation factor 6 (ARF6) is a GTP-binding protein pivotal in regulating endocytic recycling, cytoskeleton remodeling, and mitotic cytokinesis. It plays a crucial role in actin cytoskeleton reorganization, stress fiber formation, dendritic spine development, and membrane trafficking. ARF6 is essential for maintaining adherens junction protein levels, such as CDH1, and is involved in NTRK1 sorting in the recycling pathway.
Therapeutic significance:
Understanding the role of ADP-ribosylation factor 6 could open doors to potential therapeutic strategies.